1. Immunology/Inflammation
  2. NOD-like Receptor (NLR)
  3. NX-13

NX-13 

Cat. No.: HY-141521
Handling Instructions

NX-13 is a safe, selective, orally active and well-tolerated novel small molecule. NX-13 targets and activates NLRX1 to induce immunometabolic changes resulting in lower inflammation and responses in inflammatory bowel disease. NX-13 is a promising drug for crohn’s disease and ulcerative colitis research.

For research use only. We do not sell to patients.

NX-13 Chemical Structure

NX-13 Chemical Structure

CAS No. : 2389235-01-0

Size Price Stock
5 mg USD 300 Ask For Quote & Lead Time
10 mg USD 480 Ask For Quote & Lead Time
25 mg USD 950 Ask For Quote & Lead Time
50 mg USD 1450 Ask For Quote & Lead Time
100 mg USD 2250 Ask For Quote & Lead Time

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

NX-13 is a safe, selective, orally active and well-tolerated novel small molecule. NX-13 targets and activates NLRX1 to induce immunometabolic changes resulting in lower inflammation and responses in inflammatory bowel disease. NX-13 is a promising drug for crohn’s disease and ulcerative colitis research[1].

IC50 & Target[1]

NLRX1

 

In Vivo

NX-13 (1 and 10 mg/kg; oral gavage; 0~24 hours) reaches the distal gastrointestinal tract[1].
NX-13 (0, 500, or 1000 mg/kg; oral gavage; 7 days) reduces ALP levels[1].
NX-13 (10 or 100 mg/kg; oral gavage; 0~24 hours) high concentration has higher elimination rate constant and lower half-life[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL/6J mice (8-10 weeks age)
Dosage: 1 and 10 mg/kg (Pharmacokinetics analysis)
Administration: Oral gavage; 24 hours
Result: NX-13(10 mg/kg) reached the distal gastrointestinal tract.
Animal Model: Sprague Dawley rats (six weeks age)
Dosage: 0, 500, or 1000 mg/kg
Administration: Oral gavage; 7 days
Result: ALP in rats given the 1000 mg/kg dose level was lower than that in rats given 500 mg/kg.
Animal Model: Male jugular vein catheterized Sprague Dawley rats (six weeks age)
Dosage: 10 or 100 mg/kg (Pharmacokinetics analysis)
Administration: Oral gavage; 0~24 hours
Result: NX-13(100 mg/kg) had a higher elimination rate constant and a lower half-life than NX-13(10mg /kg).
Molecular Weight

399.44

Formula

C₂₄H₂₁N₃O₃

CAS No.
SMILES

CC1=NC(OC2=CC(OC3=CC=CC(C)=N3)=CC(OC4=CC=CC(C)=N4)=C2)=CC=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

NX-13NX13NX 13NOD-like Receptor (NLR)SelectiveOralWell-toleratedImmunometabolicInflammationCrohnUlcerativeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
NX-13
Cat. No.:
HY-141521
Quantity:
MCE Japan Authorized Agent: